Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
complement inhibitor |
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L04AA54
|
| gptkbp:brand |
gptkb:Empaveli
gptkb:Aspaveli |
| gptkbp:CASNumber |
2028263-64-7
|
| gptkbp:chemicalFormula |
C192H296N52O64
|
| gptkbp:developer |
gptkb:Apellis_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
pegcetacoplan
|
| gptkbp:indication |
gptkb:paroxysmal_nocturnal_hemoglobinuria
geographic atrophy secondary to age-related macular degeneration |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
C3 complement inhibitor
|
| gptkbp:pregnancyCategory |
unknown
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
diarrhea
abdominal pain fatigue injection site reaction infections |
| gptkbp:target |
gptkb:complement_component_3_(C3)
|
| gptkbp:UNII |
6QY1D9Y4F1
|
| gptkbp:usedFor |
gptkb:geographic_atrophy
gptkb:paroxysmal_nocturnal_hemoglobinuria |
| gptkbp:bfsParent |
gptkb:Empaveli
gptkb:Syfovre gptkb:geographic_atrophy |
| gptkbp:bfsLayer |
8
|